U.S. markets open in 1 hour 31 minutes

Aurinia Pharmaceuticals Inc. (AUPH)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
14.01+0.61 (+4.55%)
At close: 4:00PM EDT
14.01 0.00 (0.00%)
Pre-Market: 07:48AM EDT
Sign in to post a message.
  • J
    Jon
    Hound and Wayne, please comment on today's $SRNE news tilled "Sorrento Enters Into Multi-Year Cooperative Research and Development Agreement With the U.S. Naval Medical Research Unit – No. 3 (NAMRU-3) For Pandemic Preparedness Combating COVID-19." Yahoo published the SSRNE news at 1:46 pm : https://finance.yahoo.com/quote/SRNE?p=SRNE Will you insist on saying both SRNE CEO Henry Ji and Ariadinvestor are from Chinese Communist Party ? Thanks!
  • A
    Ariadinvestor
    Quite a few of my followers such as Jack, Singer, Dan & K Smooth did start to accumulate $SRNE at $2--, but they didn't dump their $AUPH gold bags. 🙏 Sandeman: "Ariadinvestor is quirky AF and has been bashed for years. With that said, if everyone listened to his 3 calls before they exploded, you would be a freaking millionaire." cyaaa replied: "I have been with AriadInvestor since Ariad. All his recommendations so far made myself very good returns. Still in AUPH and in SRNE. Thank you Ariadinvestor!!" Just a matter of time short squeeze is! @Hound/BooHoo/Jt/M 👈 You've never followed me!
    Bullish
  • A
    Ariadinvestor
    I'm also accused of being a short seller. 👉 To Hound, Wayne, Jerry, WildBill / whoever accuses me of being a short: Let's swear to God I would burn in hell if I was a short, or your whole clan will burn in hell. I still own far more $SRNE shares than Justin, who said he owned far more shares & asked me to leave, although I took some profits @ $10 & $18.82 on 05/18/20 & 08/10/20 "to take out cost basis & free roll it" in K Smooth's words.
    Bullish
  • m
    mayweather
    (http://Fairstox.com) is a must for any trader. Their watchlist which covers pre-market movers is one of the best researched in the industry. I don’t start trading without reading their daily email each morning!
  • J
    JACK
    I did it!

    s-auph
    b-srne

    too much upside though auph still a good stock!
  • J
    JACK
    I often wonder what I will do until I do it, but really thinking about cashing out auph for srne.........
  • O
    Observer
    Singer: "I became a millionaire in 2021, thanks to Ariadinvestor and his unfailing support for AUPH! Now holding on for an even bigger payoff with SRNE!!!" https://finance.yahoo.com/quote/SRNE/community?messageId=fe4a537f-4b98-47f5-9f87-f0fcc991fcde&replyId=07969322-ace3-4a3b-8de9-b458bbf4e010 Wayne is dead wrong saying everyone mutes Ariadinvestor.

    Wayne is dead wrong saying everyone mutes Ariadinvestor. At least Singer does not mute Ariadinvestor.

    Ariadinvestor: "Those who listen to me and buy & hold the AUPH/SRNE gold bags will make big money as it has been proven that those who listened to me and bought & held the ARIA gold bags have made big money. Peter Lynch: 'If you like a stock at $14 and it goes to $6, that's good if you understand the company. Take advantage of these declines.' Long live $SRNE / $AUPH short squeeze !"
    Bullish
  • H
    Hound
    Ariadwwwaakkooo is promoting dumping AUPH for the PR pump shop $SRNE. Is that thing getting paid by SRNE to pump ? Wouldn't be the first time some suspect company has done that. $SRNE suddenly had a pipeline full of therapies with "covid" in the name when the pandemic broke out. Does a legit company change the name of a therapy already in development to match the current health scare ?
  • A
    Anonymous
    Huge volume on $15/16 July 16 options

    Substantial open interest .

    $13-$16 total 26,000 options

    Gl!
  • C
    Chip
    AUPH to HOD up +3.25%. GSK CEO Emma Walmsley will host a virtual investor event tomorrow at 8:00 a.m. ET. GSK previously said, "The update will provide a clear view of the strategy for New GSK, its outlook for growth, and the opportunities the company sees for shareholder value creation."

    I have no idea if GSK and AUPH are dance partners and if they will announce a buyout, but AUPH is performing better. In May the London Times indicated GSK could be an AUPH buyer.
  • C
    Chip
    The ode to AUPH after a dreary week in the markets: June 18, 2021

    Starting at 3:51 p.m. AUPH became under accumulation with volume bar spikes averaging about 75,000 shares per 1-minute tick. There was a MOC order for a 2 million share block bought at the close at exactly 4:00 p.m. at $13.00. On Monday, June 14, 2021, AUPH announced effective today the appointment of Dr. Brinda Balakrishnan, M.D., Ph.D., was appointed to the Company’s Board of Directors effective June 14, 2021 (the same day).

    At BioMarin, Dr. Balakrishnan leads initiatives on corporate strategy, mergers, and acquisitions, partnering, and licensing. Deloitte wrote on June 15, 2021, "As businesses slowly start opening up and moving towards pre-COVID-19 growth levels, Mergers and Acquisitions (M&A) are also gradually reviving. As per the latest M&A trends survey conducted by Deloitte, 61 percent of US dealmakers expect M&A activity to return to pre-COVID-19 levels within the next 12 months.

    According to Investopedia, “Once an (M&A) agreement between two companies is reached, and the due diligence finalized, both companies will decide on the final type of sale. The companies will determine if a sale will be made through the purchase of assets or through the purchase of stock. The acquirer will then finalize its financing arrangement for the purchase.”

    Merger Monday is a term invented by Wall Street to denote the fact that major players in the market often finalize major mergers and acquisitions during the weekend and announce them on Monday. The goal for Monday announcements is to help sway stock prices in favor of the companies making major plays in the market.

    Will AUPH announce a merger on Monday, June 21, 2021? I have no idea. Maybe, maybe not. Here are 5 facts I do know.

    • On May 6th Seeking Alpha wrote, “AUPH rose 5.5% in premarket trading on some speculation about potential takeover interest. AZN and GSK are speculated to be interested in Aurinia, according to The London Times. The newspaper says there are 'whispers' that the AZN and GSK are 'sniffing around' AUPH."

    • On June 14th, AUPH appointed an M.D., who also has a Ph.D., that in her current Biotech position “leads initiatives on corporate strategy, mergers and acquisitions, partnering and licensing.”

    • On June 15th Deloitte, as one of the Big Four accounting organizations and the largest professional services network in the world by revenue and number of professionals, with headquarters in London, England, announced on their website, “Mergers and Acquisitions (M&A) are also gradually reviving.”

    • On June 18th, AUPH experienced material share accumulation starting 9 minutes before the close (Does somebody know something?).

    • GSK, AZN, Deloitte, & The Times are all located in London (Coincidental? Maybe, maybe not).

    Will AUPH and a merger partner be announced on Monday? I have no idea. Maybe, maybe not. Could due diligence have been completed and final M&A terms are now being negotiated? Maybe, maybe not. Was Dr. Balakrishnan selected by AUPH's Board for immediate advisory to maximize shareholder value? Maybe, maybe not.

    Regardless, there was a lot of buying of AUPH's security starting at 3:51 p.m. ET into today's close with somebody ponying up $26 million in the common. Who has the type of money to do that amount of purchases and why did they buy the stock?
    Bullish
  • J
    Jimmy
    From years of options analysis, predicting a takeover by July expiration...JMHO
  • H
    H E
    Given the current security's laws and the fiduciary duties owed to AUPH shareholders by BOD members, I doubt that Dr. Balakrishnan and her company are involved in a possible merger or tie up with AUPH. The access to inside information she would have would be a prohibited conflict of interest. If a takeover occurs by the end of the year, I would be pleasantly surprised.
  • C
    Chip
    AUPH was up +3.9% today and after some profit-taking is now up +2.31%.

    On Wednesday, June 23, 2021, 8:00 a.m. ET, GlaxoSmithKline PLC (GSK) CEO Emma Walmsley & other execs will host a virtual investor event. The update will provide a clear view of the strategy for New GSK, its outlook for growth and the opportunities the company sees for shareholder value creation.

    On May 6th Seeking Alpha wrote, “Aurinia (AUPH) rose 5.5% in premarket trading on some speculation about potential takeover interest. AZN and GSK are speculated to be interested in Aurinia, according to The London Times. The newspaper says there are 'whispers' that the AZN and GSK are 'sniffing around' AUPH."

    I strongly believe at some point, maybe later this year, AUPH will be bought out. Why?

    Despite spending billions on R&D, big pharma doesn't usually discover new molecules that eventually become an FDA-approved drug to bring to the marketplace like XBI biotechs. Instead, it's often the smaller biotechs that are the leaders in discovering promising new therapeutic approaches. Big pharma can buy a biotech company, obtain their product, develop/acquire a new revenue stream to expand their profits, and obtain more brainpower.

    Could AUPH be acquired on Tuesday or Wednesday? Who knows? Maybe, maybe not, but I believe a deal is forthcoming in the not-too-distant. And, the good news for those of us holding AUPH's security? The stock price is climbing higher.
    Bullish
  • W
    Wayne
    Copy/Paste from Seeking Alpha: Benlysta, the GSK drug approved for SLE in 2011, was approved for LN in December 2020. While the efficacy of Lupkynis (42.3% complete response after 1 year of therapy vs 23.3% for standard of care) is substantially better than Benlysta (32.5% efficacy vs. 25.5% for standard of care), GSK has the advantage of an established brand for SLE and a decade of safe use. The problem GSK has is that large numbers of patients have already tried or are currently using Benlysta. If Benlysta is not controlling SLE and patients advance to LN, they will be looking for an alternate treatment - a good situation for Lupkynis.

    Excellent reading materials:
    https://seekingalpha.com/article/4435797-aurinia-pharmaceuticals-recent-sell-off-provides-great-entry-point
    Bullish
  • T
    The Horse
    I know its 8 days old but one must wonder why the good doc who is educated at MIT/Harvard and who is employed with BioMarin and who specialises in mergers and acquisitions is on AUPH's Board. Just doesn't make sense!

    Dr. Balakrishnan is Group Vice President, Corporate and Business Development of BioMarin Pharmaceutical Inc. (“BioMarin”), a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare disorders. At BioMarin, Dr. Balakrishnan leads initiatives on corporate strategy, mergers and acquisitions, partnering and licensing.
  • C
    Chip
    EARLY EDITION - Pre Market Catalyst Event Extract: Saturday, June 19, 2021, 06:31 a.m. ET

    Wednesday - June 23, 2021, 8:00 a.m. ET - GlaxoSmithKline plc (GSK) CEO Emma Walmsley and other execs host a virtual investor event. The update will provide a clear view of the strategy for New GSK, its outlook for growth and the opportunities the company sees for shareholder value creation. On May 6th Seeking Alpha wrote, “AUPH rose 5.5% in premarket trading on some speculation about potential takeover interest. AZN and GSK are speculated to be interested in Aurinia, according to The London Times. The newspaper says there are 'whispers' that the AZN and GSK are 'sniffing around' AUPH."
  • K
    Kurt
    Since Dr. Balakrishan joined the board there have been more Green days.
  • C
    Chip
    Pre Market Catalyst Event Extract: Saturday, June 19, 2021, 07:27 a.m. ET

    Wednesday - June 23, 2021, 8:00 a.m. ET - GlaxoSmithKline plc (GSK) CEO Emma Walmsley and other execs host a virtual investor event. The update will provide a clear view of the strategy for New GSK, its outlook for growth and the opportunities the company sees for shareholder value creation. On May 6th Seeking Alpha wrote, “AUPH rose 5.5% in premarket trading on some speculation about potential takeover interest. AZN and GSK are speculated to be interested in Aurinia, according to The London Times. The newspaper says there are 'whispers' that the AZN and GSK are 'sniffing around' AUPH."

    Question: What information will GSK CEO Emma Walmsley provide to investors on Wednesday on her "clear view of the strategy for New GSK, its outlook for growth and the opportunities the company sees for shareholder value creation?"
    Bullish
  • s
    sharon
    Rev Shark added shares this morning......his track record is in par with being a winner.....a few years back AIMT was his pick for the year and it did get FDA approval for their peanut allergy drug and the stock did nothing for months just as auph has underperfomed since the FDA nod..... then one day months after FDA approval the stock was up 25 pts or so on a buyout ~~~ Nestle bought AIMT.....the Shark thinks highly of Aurinia regarding a buyout but it has not happened so we wait for the stock to go up on its own merits and it should given the blockbuster drug that just hit the market......COVID is a nuisance for sales ~~ fingers crossed that has changed with the re-opening!! go auph ~~~~